ArticleFrontiers in medicine2026
Early postoperative C-reactive protein-to-albumin ratio for risk stratification of osteomyelitis recurrence after surgical treatment.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Reliable biomarkers for identifying patients at increased risk of osteomyelitis recurrence during the early postoperative period are lacking. The C-reactive protein-to-albumin ratio (CAR), which integrates systemic inflammatory burden and nutritional status, has shown diagnostic value in musculoskeletal infections, but its prognostic role after surgical treatment of osteomyelitis remains unclear. This study evaluated whether early postoperative CAR predicts osteomyelitis recurrence and compared its performance with conventional inflammatory biomarkers. Patients and methods: This retrospective cohort study included 90 consecutive adults who underwent surgical treatment for osteomyelitis between January 2020 and December 2024. Serum inflammatory biomarkers were recorded before surgery and at the first postoperative outpatient visit, approximately one month after surgery. The primary outcome was osteomyelitis recurrence during a minimum follow-up of 12 months. Receiver operating characteristic (ROC) analysis was used to evaluate the predictive performance of inflammatory biomarkers, and multivariable logistic regression was used to evaluate factors independently associated with recurrence. Results: During a mean follow-up of 19 months, recurrence occurred in 19 patients (21.1%). Patients with recurrence had significantly higher baseline and one-month CAR values than those without recurrence (both Conclusion: Early postoperative CAR was associated with osteomyelitis recurrence and showed good discriminative ability, with the numerically highest AUC among the evaluated inflammatory biomarkers. However, its discriminative performance was not statistically superior to that of one-month CRP. CAR may therefore represent a practical adjunctive biomarker for postoperative risk stratification. Prospective multicenter studies are warranted to validate these findings and determine whether CAR-guided surveillance improves patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.